

Sarah M Bronner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9274195/publications.pdf>

Version: 2024-02-01

17
papers

1,459
citations

567281

15
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

2784
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 15-23.	2.2	16
2	Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2018, 28, 867-873.	5.0	62
3	USP7 small-molecule inhibitors interfere with ubiquitin binding. <i>Nature</i> , 2017, 550, 534-538.	27.8	258
4	GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9162-9183.	6.4	77
5	Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4370-4376.	2.2	13
6	A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 10151-10171.	6.4	21
7	Enabling drug discovery project decisions with integrated computational chemistry and informatics. <i>Journal of Computer-Aided Molecular Design</i> , 2017, 31, 287-291.	2.9	7
8	ROR β antagonists and inverse agonists: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 101-112.	5.0	74
9	Transition-Metal-Free Synthesis of Tertiary Aminocyclopropanes. <i>Organic Letters</i> , 2016, 18, 6448-6451.	4.6	33
10	Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5391-5402.	6.4	95
11	Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition. <i>Journal of Biological Chemistry</i> , 2016, 291, 13014-13027.	3.4	58
12	Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 10549-10563.	6.4	69
13	Recent progress on nuclear receptor ROR β modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4387-4393.	2.2	79
14	Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637). <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 531-536.	2.8	87
15	Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1271-1298.	6.4	171
16	Genomic Analysis of Smoothed Inhibitor Resistance in Basal Cell Carcinoma. <i>Cancer Cell</i> , 2015, 27, 327-341.	16.8	316
17	A new regulatory switch in a JAK protein kinase. <i>Proteins: Structure, Function and Bioinformatics</i> , 2011, 79, 393-401.	2.6	23